COVID-19 vaccine induced Guillain-Barre syndrome: a case report
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20223365Keywords:
COVID-19 vaccine, COVID-19, Corbevax®, Guillain-Barre syndromeAbstract
Guillain-Barre syndrome (GBS) is a rare immune mediated clinical disorder of the peripheral nerves. A number of vaccines including COVID-19 vaccine have been shown to be associated with an increased risk of GBS. We reported a case of Corbevax® (COVID-19 vaccine) induced GBS. A 12 years old girl presented to the paediatric emergency with 2 days history of progressive weakness of all four limbs. The weakness started after one day of patient received her first dose of Corbevax®. Neurological examination findings were weakness, decreased muscles tone, decreased muscles power, diminished or absent deep tendon reflexes of all four limbs. The findings of cerebrospinal fluid showed increase in protein and normal cell count. The diagnosis of GBS was confirmed by nerve conduction studies. After confirmation of the diagnosis, she was given intravenous immunoglobulin (IVIG) with the dose of 2 g/kg body weight divided over 5 consecutive days. Then the patient was examined, clinical condition was improved dramatically. GBS rarely caused by COVID-19 vaccination. GBS may become life threatening due to respiratory muscles involvement. In about 30% of cases may require admission in Intensive Care Unit and need for mechanical ventilatory support. So careful monitoring is required after administration of COVID-19 vaccine. This case report never discourages the vaccine rollout, but monitoring of evolving data should be carried on by manufacturers and independent authorities coming to a definite conclusion.
Metrics
References
Atzenhoffer M, Auffret M, Pegat A, Masmoudi K, Khouri C, Bertin B, et al. Guillain-Barré Syndrome Associated with COVID-19 Vaccines: A Perspective From Spontaneous Report Data. Clin Drug Investig. 2022;42(7):581-92.
Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve. 2020;62(4):485-91.
Tamborska AA, Singh B, Leonhard SE, Hodel EM, Stowe J, Watson-Fargie T, et al. Guillain-Barré syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study. BMJ Neurol Open. 2022;4(2):e000309.
Jacobs BC, Rothbarth PH, Meché FG, Herbrink P, Schmitz PI, Klerk MA, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110-5.
Loo LK, Salim O, Liang D, Goel A, Sumangala S, Gowda AS, et al. Rajabally. Acute onset of polyradiculoneuropathy after SARS-CoV2 vaccine in the West and North Midlands, United Kingdom. Muscles Nerve 2022;65(2):233-7.
Goudarzi S, Esmaeeli S, Valencia JD, Lu ME, Hales RR, Fehnel CR, et al. Treatment Options for COVID-19-Related Guillain-Barré Syndrome: A Systematic Review of Literature. Neurologist. 2021;26(5):196-224.
Oo WM, Giri P, Souza A. AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link? J Neuroimmunol. 2021;360:577719.
Jacobs BC, Rothbarth PH, Meché FG, Herbrink P, Schmitz PI, Klerk MA, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110-5.
